Is a patch better than a pill for estrogen therapy?

The route genuinely changes the pharmacology, not just the marketing.

Oral estradiol passes through the liver first, which converts a large share of it to estrone, creating roughly a fivefold excess of estrone over estradiol at typical doses, and increases liver protein production, including a protein that binds sex hormones. Transdermal delivery (patch, gel, spray) largely bypasses this. The clearest consequence is on blood clot risk: in a large observational study of over 80,000 clot cases, oral hormone therapy was associated with increased clot risk while transdermal was not. No randomized trial has ever directly compared oral versus transdermal estradiol with blood clots as the primary outcome, so this conclusion, while consistent and biologically coherent, rests on observational data, not a randomized trial.

What to know about this answer

Most of the field treats transdermal as the safer default given the clotting data, but at least one respected clinician cautions against dismissing oral entirely, and both sides are working from observational data rather than a head-to-head randomized trial.

What the research shows, and which source each finding rests on

At oral estradiol 1 mg, mean serum estradiol was 42.3-45.6 pg/mL while mean estrone was 214-242 pg/mL, roughly a fivefold excess of estrone over estradiol, a pattern of first-pass liver conversion that transdermal delivery largely avoids

B [1]

In a nested case-control study of 80,396 blood clot cases and 391,494 controls, oral hormone therapy was associated with increased venous thromboembolism (adjusted odds ratio 1.58) while transdermal preparations were not (adjusted odds ratio 0.93); no randomized trial has ever compared oral versus transdermal estradiol with blood clots as a primary endpoint

C [2]

Higher-dose transdermal estrogen was associated with increased stroke risk while low-dose transdermal was not

C [3]

Where the real disagreement is

Each position is shown with its own sources. A position listed here is not necessarily the accepted view.

Transdermal should be the default

Most of the field, and UK guideline bodies

The clotting risk difference between oral and transdermal is consistently observed, biologically coherent given the liver's role in producing clotting factors, and corroborated across several independent observational studies, so transdermal is treated as the safer default, especially for anyone with an elevated baseline clot risk such as smokers.

C [2]

Oral should not be taken off the table

At least one prominent clinician in the field

All the route-comparison data are observational, oral estradiol is cheaper, has no adhesion or skin-irritation issues, is preferred by some women, and the absolute clot risk in healthy women under 60 is low; a categorical preference for transdermal shouldn't become a rule that excludes oral for everyone.

B [1]

What would settle it: A randomized controlled trial of oral versus transdermal estradiol with blood clot risk as the primary endpoint; this has never been done.

What is really going on here

Is the route recommendation I'm getting based on an actual randomized trial, or on consistent but observational data?
Do I have a personal risk factor, like smoking or a prior clot, that would make the route choice matter more for me specifically?
Am I being told oral estrogen is unsafe outright, or that it carries a different, generally low, absolute risk?

Questions for your doctor

Given my personal risk factors, would transdermal or oral estradiol make more sense for me?
What is my absolute, not just relative, risk of a blood clot on either route, given my age and health history?
If I start on one route, what would make you consider switching me to the other?
Are there practical factors, like cost, skin sensitivity, or convenience, that should factor into this choice for me?

Questions with no answer yet

Does the observed clot-risk difference between oral and transdermal estradiol reflect a true causal effect of the route, or could it partly reflect which women are prescribed which route in real-world practice?

Partly studied

What is known: The clot-risk difference is consistently observed and biologically coherent, since oral dosing produces a measured fivefold excess of estrone over estradiol and raises liver-produced clotting-related proteins that transdermal dosing largely avoids, and it is corroborated across several independent observational studies; but no randomized controlled trial has ever compared oral versus transdermal estradiol with blood clots as the primary outcome.

What would test it: A randomized controlled trial of oral versus transdermal estradiol with blood clot risk as the primary endpoint; this has never been done.

Is there a dose or duration of oral estradiol use in healthy women under 60 where the absolute clot risk is low enough that the route choice stops mattering in practice?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: The source material notes that the absolute clot risk in healthy women under 60 is low on either route, but does not identify a study that defines a specific dose or duration threshold below which the route choice becomes clinically immaterial.

What would test it: A dose-stratified analysis of existing observational cohorts, or a dedicated trial, identifying whether a low-dose, short-duration oral regimen carries measurably different risk than standard oral dosing.

Sources

1.Estradiol and progesterone bioavailability for moderate to severe vasomotor symptom treatment and endometrial protection with the continuous-combined regimen of TX-001HR (oral estradiol and progesterone capsules).Lobo RA, et al. Estradiol and progesterone bioavailability for moderate to severe vasomotor symptom treatment and endometrial protection with the continuous-combined regimen of TX-001HR (REPLENISH). Menopause 2019;26(7):720-727. · Randomised trial
2.Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases.Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ 2019;364:k4810. · Observational study
3.Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study.Renoux C, Dell'Aniello S, Garbe E, Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke. BMJ 2010;340:c2519. · Observational study

The letter grades the type of study behind a claim, not the answer itself.

This page is general information based on published research and public sources. It is not medical advice and not a personal assessment, and it does not replace a conversation with your doctor. Peritale is a wellness product, not a medical device, and is not intended to diagnose, treat, cure or prevent any disease. For any medical question, speak with a licensed clinician.

You are not imagining it

In about seven minutes on your phone, Peritale reads five signal systems and maps your symptoms, so you can see that what you feel is real, follow your hormonal transition over time, and walk into your doctor ready to ask for the care you deserve. Your first check is free, no credit card.

Start Free Mapping